- Author
-
V.N. Nduba
- Title
- TB vaccine trials in Kenya
- Subtitle
- Preparation and implementation
- Supervisors
-
M.W. Borgdorff
- Co-supervisors
-
A.H. van 't Hoog
K.F. Laserson - Award date
- 10 June 2020
- Number of pages
- 172
- ISBN
- 9789402820102
- Document type
- PhD thesis
- Faculty
- Faculty of Medicine (AMC-UvA)
- Abstract
-
BCG, the only licensed vaccine against tuberculosis in use today, protects against severe extrapulmonary forms of TB in humans (miliary and meningeal forms), but offers variable protection against the most common respiratory form of the disease (pulmonary TB), with ranges of efficacy from 0-80% and can produce severe adverse effects in immunocompromised individuals. New vaccines are key to the global effort to eliminate TB. New vaccines will need to protect against pulmonary, extrapulmonary and disseminated TB in all populations and are urgently needed. A vaccine strategy that targets adults and adolescents to reduce TB transmission and infants to reduce TB morbidity and mortality would have great impact on the TB epidemic. TB vaccine trial sites will need to be located in high burden settings and have the infrastructure, staffing and necessary experience to conduct such trials. At the time of conducting epidemiological studies reported in this thesis, Kenya was ranked 10th by the WHO among countries with the greatest burden of tuberculosis. Western Kenya had a high burden of TB (400/100,000 population) and HIV prevalence (15%), with 75% of TB cases also HIV infected. Epidemiological studies were conducted among adolescents and infants to determine the burden of tuberculosis and inform future TB vaccine trial design. Subsequently, the site took part in two multicenter TB vaccine trials in infants and adults that are also reported in this thesis.
- Persistent Identifier
- https://hdl.handle.net/11245.1/7df93793-6ae7-4e11-a79f-eaf6a26c53d7
- Downloads
-
Thesis (complete)
Front matter
Chapter 1: General introduction
Chapter 2: Prevalence of tuberculosis in adolescents, western Kenya: Implications for control programs
Chapter 3: Incidence of active tuberculosis and cohort retention among adolescents in western Kenya
Chapter 4: Estimating the annual risk of infection with Mycobacterium tuberculosis among adolescents in western Kenya in preparation for TB vaccine trials
Chapter 5: Phase 2b placebo-controlled trial of M72/AS01E candidate vaccine to prevent active tuberculosis in adults
Chapter 6: The incidence of tuberculosis in infants, Siaya District, western Kenya
Chapter 7: Chest radiographs for pediatric TB diagnosis: Inter-rater agreement and utility
Chapter 8: A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants
Chapter 9: General discussion
Summary; Samenvatting; Acknowledgements; Resume of the author; Portfolio
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library, or send a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.